DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DBD - US2536512021 - Common Stock
67.68 USD
+0.03 (+0.04%)
67.68 USD
0 (0%)
DBD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 35 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has only an average score on both its financial health and profitability. DBD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year DBD was profitable.
DBD had a positive operating cash flow in the past year.
DBD had negative earnings in 4 of the past 5 years.
In multiple years DBD reported negative operating cash flow during the last 5 years.
1.2 Ratios
DBD's Return On Assets of 1.36% is fine compared to the rest of the industry. DBD outperforms 62.86% of its industry peers.
DBD has a Return On Equity of 4.57%. This is in the better half of the industry: DBD outperforms 74.29% of its industry peers.
With a decent Return On Invested Capital value of 8.85%, DBD is doing good in the industry, outperforming 71.43% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DBD is significantly below the industry average of 15.26%.
The last Return On Invested Capital (8.85%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROIC | 8.85% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
With a decent Profit Margin value of 1.37%, DBD is doing good in the industry, outperforming 62.86% of the companies in the same industry.
Looking at the Operating Margin, with a value of 7.47%, DBD is in the better half of the industry, outperforming 77.14% of the companies in the same industry.
In the last couple of years the Operating Margin of DBD has grown nicely.
Looking at the Gross Margin, with a value of 25.48%, DBD is doing worse than 60.00% of the companies in the same industry.
In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
DBD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, DBD has about the same amount of shares outstanding.
Compared to 5 years ago, DBD has less shares outstanding
The debt/assets ratio for DBD has been reduced compared to a year ago.
2.2 Solvency
DBD has an Altman-Z score of 1.96. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.96, DBD perfoms like the industry average, outperforming 51.43% of the companies in the same industry.
The Debt to FCF ratio of DBD is 3.71, which is a good value as it means it would take DBD, 3.71 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DBD (3.71) is better than 68.57% of its industry peers.
DBD has a Debt/Equity ratio of 0.84. This is a neutral value indicating DBD is somewhat dependend on debt financing.
DBD has a worse Debt to Equity ratio (0.84) than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Altman-Z | 1.96 |
ROIC/WACC0.94
WACC9.41%
2.3 Liquidity
DBD has a Current Ratio of 1.36. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
DBD has a Current ratio of 1.36. This is comparable to the rest of the industry: DBD outperforms 48.57% of its industry peers.
DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.89, DBD is in line with its industry, outperforming 54.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
DBD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.07%.
The Earnings Per Share has been growing by 69.69% on average over the past years. This is a very strong growth
The Revenue has decreased by -2.86% in the past year.
Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -3.18% on average per year.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
3.2 Future
The Earnings Per Share is expected to grow by 19.21% on average over the next years. This is quite good.
Based on estimates for the next years, DBD will show a small growth in Revenue. The Revenue will grow by 2.51% on average per year.
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.49 indicates a rather expensive valuation of DBD.
77.14% of the companies in the same industry are more expensive than DBD, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.54. DBD is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 13.77, DBD is valued correctly.
DBD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DBD is cheaper than 62.86% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.78, DBD is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.49 | ||
| Fwd PE | 13.77 |
4.2 Price Multiples
DBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DBD is cheaper than 94.29% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 82.86% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.65 | ||
| EV/EBITDA | 7.5 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DBD does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as DBD's earnings are expected to grow with 19.21% in the coming years.
PEG (NY)2.09
PEG (5Y)N/A
EPS Next 2Y12.85%
EPS Next 3Y19.21%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
67.68
+0.03 (+0.04%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.36%
Inst Owner Change-2.66%
Ins Owners1.82%
Ins Owner Change0%
Market Cap2.43B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target80.58 (19.06%)
Short Float %2.16%
Short Ratio4.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)4.41%
PT rev (3m)4.41%
EPS NQ rev (1m)0.83%
EPS NQ rev (3m)11.47%
EPS NY rev (1m)13.35%
EPS NY rev (3m)20.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.49 | ||
| Fwd PE | 13.77 | ||
| P/S | 0.66 | ||
| P/FCF | 9.65 | ||
| P/OCF | 8.69 | ||
| P/B | 2.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.5 |
EPS(TTM)3.66
EY5.41%
EPS(NY)4.92
Fwd EY7.26%
FCF(TTM)7.01
FCFY10.36%
OCF(TTM)7.79
OCFY11.51%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)2.09
PEG (5Y)N/A
Graham Number50.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROCE | 11.2% | ||
| ROIC | 8.85% | ||
| ROICexc | 9.91% | ||
| ROICexgc | 29.15% | ||
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% | ||
| FCFM | 6.82% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 20.59% | ||
| Cap/Sales | 0.75% | ||
| Interest Coverage | 2.89 | ||
| Cash Conversion | 68.06% | ||
| Profit Quality | 497.23% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.96 |
F-Score7
WACC9.41%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y14.01%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%
DIEBOLD NIXDORF INC / DBD FAQ
What is the fundamental rating for DBD stock?
ChartMill assigns a fundamental rating of 4 / 10 to DBD.
What is the valuation status for DBD stock?
ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.
What is the profitability of DBD stock?
DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.
How financially healthy is DIEBOLD NIXDORF INC?
The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.
Can you provide the dividend sustainability for DBD stock?
The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.